Angela Wright1, Jacqueline Diebold2, Jaskiran Otal2, Carly Stoneman3, Jonathan Wong2, Christine Wallace3, Mark Duffett4. 1. St. Joseph's Healthcare Hamilton, 50 Charlton Ave E, Hamilton, ON, L8N 4A6, Canada. wrighta@stjosham.on.ca. 2. Hamilton Health Sciences, Hamilton, ON, Canada. 3. St. Joseph's Healthcare Hamilton, 50 Charlton Ave E, Hamilton, ON, L8N 4A6, Canada. 4. Departments of Pediatrics and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
Abstract
BACKGROUND: Abrupt discontinuation of benzodiazepines often results in side effects including anxiety and insomnia, which can be barriers to discontinuation among long-term users. Melatonin improves the onset, duration, and quality of sleep. By preventing insomnia in those attempting to discontinue benzodiazepines, melatonin may facilitate benzodiazepine discontinuation. OBJECTIVES: The primary objective was to determine the effect of melatonin compared with placebo on benzodiazepine discontinuation in adults attempting to discontinue benzodiazepines. The secondary objective was to determine the effect of melatonin on sleep quality in this population. METHODS: We searched PubMed, MEDLINE, EMBASE, PsychINFO, and ClinicalTrials.gov from inception to November 2014. We included randomized controlled trials published in English comparing melatonin with placebo that reported benzodiazepine discontinuation or sleep quality. Two reviewers independently screened trials, extracted data, and assessed the risk of bias. RESULTS: We included six trials randomizing 322 participants. The mean age of participants was approximately 64 years. The trials used varied tapering strategies to discontinue benzodiazepines over 4-10 weeks while using melatonin. Melatonin had no effect on the odds of successfully discontinuing benzodiazepines (odds ratio 0.72, 95% confidence interval 0.21-2.41, p = 0.59). There was important heterogeneity among the trials (I (2) = 76%). The effect of melatonin on sleep quality was inconsistent. CONCLUSIONS: Melatonin had no effect on benzodiazepine discontinuation while the effect of melatonin on sleep quality was inconsistent. We cannot rule out a role of melatonin in improving benzodiazepine discontinuation or sleep quality owing to imprecise effect estimates. Larger, well-designed, and reported randomized controlled trials may provide more valid and precise estimates of the effect of melatonin on these outcomes.
BACKGROUND: Abrupt discontinuation of benzodiazepines often results in side effects including anxiety and insomnia, which can be barriers to discontinuation among long-term users. Melatonin improves the onset, duration, and quality of sleep. By preventing insomnia in those attempting to discontinue benzodiazepines, melatonin may facilitate benzodiazepine discontinuation. OBJECTIVES: The primary objective was to determine the effect of melatonin compared with placebo on benzodiazepine discontinuation in adults attempting to discontinue benzodiazepines. The secondary objective was to determine the effect of melatonin on sleep quality in this population. METHODS: We searched PubMed, MEDLINE, EMBASE, PsychINFO, and ClinicalTrials.gov from inception to November 2014. We included randomized controlled trials published in English comparing melatonin with placebo that reported benzodiazepine discontinuation or sleep quality. Two reviewers independently screened trials, extracted data, and assessed the risk of bias. RESULTS: We included six trials randomizing 322 participants. The mean age of participants was approximately 64 years. The trials used varied tapering strategies to discontinue benzodiazepines over 4-10 weeks while using melatonin. Melatonin had no effect on the odds of successfully discontinuing benzodiazepines (odds ratio 0.72, 95% confidence interval 0.21-2.41, p = 0.59). There was important heterogeneity among the trials (I (2) = 76%). The effect of melatonin on sleep quality was inconsistent. CONCLUSIONS:Melatonin had no effect on benzodiazepine discontinuation while the effect of melatonin on sleep quality was inconsistent. We cannot rule out a role of melatonin in improving benzodiazepine discontinuation or sleep quality owing to imprecise effect estimates. Larger, well-designed, and reported randomized controlled trials may provide more valid and precise estimates of the effect of melatonin on these outcomes.
Authors: Richard C Oude Voshaar; Jaap E Couvée; Anton J L M van Balkom; Paul G H Mulder; Frans G Zitman Journal: Br J Psychiatry Date: 2006-09 Impact factor: 9.319
Authors: Anna Ballokova; Nancye M Peel; Daniela Fialova; Ian A Scott; Leonard C Gray; Ruth E Hubbard Journal: Drugs Aging Date: 2014-04 Impact factor: 3.923
Authors: Daniel P Cardinali; Elisa Gvozdenovich; Marcos R Kaplan; Isidoro Fainstein; Hugo A Shifis; Santiago Pérez Lloret; Liliana Albornoz; Armando Negri Journal: Neuro Endocrinol Lett Date: 2002-02 Impact factor: 0.765
Authors: Lone Baandrup; Jane Lindschou; Per Winkel; Christian Gluud; Birte Y Glenthoj Journal: World J Biol Psychiatry Date: 2015-06-18 Impact factor: 4.132
Authors: Rebecca L Gould; Mark C Coulson; Natasha Patel; Elizabeth Highton-Williamson; Robert J Howard Journal: Br J Psychiatry Date: 2014-02 Impact factor: 9.319
Authors: Tracey L Sletten; Michelle Magee; Jade M Murray; Christopher J Gordon; Nicole Lovato; David J Kennaway; Stella M Gwini; Delwyn J Bartlett; Steven W Lockley; Leon C Lack; Ronald R Grunstein; Shantha M W Rajaratnam Journal: PLoS Med Date: 2018-06-18 Impact factor: 11.069
Authors: Pawel P Posadzki; Ram Bajpai; Bhone Myint Kyaw; Nicola J Roberts; Amnon Brzezinski; George I Christopoulos; Ushashree Divakar; Shweta Bajpai; Michael Soljak; Gerard Dunleavy; Krister Jarbrink; Ei Ei Khaing Nang; Chee Kiong Soh; Josip Car Journal: BMC Med Date: 2018-02-05 Impact factor: 8.775
Authors: Juha Puustinen; Ritva Lähteenmäki; Janne Nurminen; Tero Vahlberg; Pertti Aarnio; Markku Partinen; Ismo Räihä; Pertti J Neuvonen; Sirkka-Liisa Kivelä Journal: BMC Geriatr Date: 2018-06-15 Impact factor: 3.921